Please assess the completion status of the following clinical trial:

Trial Title: A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide informed consent (for the intervention arm only)~* No prior history of confirmed COVID-19 (i.e., based on a positive FDA-approved assay for SARS-CoV-2 and no documented FDA-approved serological test results for antibodies to SARS-CoV-2 found in health system databases)~* Established ASCVD (i.e., defined as prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass surgery, ischemic stroke, and/or peripheral artery disease)~* At least 12 months of continuous health plan membership and prescription drug benefit prior to enrollment~* A registered e-mail address with the health care delivery system in order to facilitate obtaining electronic consent for study participation~Exclusion Criteria:~* Receipt of IPE on or within 12 months before the day of enrollment~* Known hypersensitivity to IPE, fish, and/or shellfish~* Documented use of any omega-3 fatty acid medications or dietary supplements containing omega-3 fatty acids in the EHR~* Women who are pregnant or planning to become pregnant~* Hospitalization for myocardial infarction and/or elective percutaneous coronary intervention within the past 1 month~* Currently receiving triple anti-thrombotic therapy~* Stage D heart failure~* Severe liver disease~* End-stage renal disease requiring chronic dialysis or estimated glomerular filtration rate \<15 mL/min/1.73 m2~* Metastatic cancer and/or receiving active systemic chemotherapy~* Institutionalized and/or receiving palliative care

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: ACTIVE_COMPARATOR): None
- Usual Care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).